TCR molecules for recognizing tumor-associated antigens and their uses
By developing TCRs that can bind to the SLLQHLIGL polypeptide-HLA-A*02 complex and transducing them into T cells, the problem of limited target selection range in the prior art is solved, and the PRAME-related tumors are achieved Efficient identification and treatment.
Patent Information
- Application Number
- CN202410237507.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-28
- Filing Date
- 2024-03-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-03-01
AI Technical Summary
The prior art is difficult to identify and select suitable targets, limiting the scope of target selection for TCR therapy, especially when targeting PRAME-related tumors, there is a lack of TCR that can specifically recognize PRAME polypeptides.
A TCR capable of binding to the SLLQHLIGL polypeptide-HLA-A*02 complex was developed. By screening and identifying the variable domain CDR1, CDR2 and CDR3 amino acid sequences of the TCR, a TCR that can specifically recognize the PRAME polypeptide was constructed, and further through Genetically engineered it to T cells for the preparation of T cells targeting PRAME-associated tumors.
The specific identification and targeting of PRAME polypeptides has been achieved, which has significantly improved the therapeutic effect on PRAME-related tumors, provided a wider target selectivity, and enhanced the targeting and effectiveness of TCR therapy.
Smart Images

Figure BDA0004723045450000151 
Figure BDA0004723045450000161 
Figure BDA0004723045450000171
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology. Specifically, the present invention relates to TCRs capable of recognizing short peptides derived from PRAME antigens and their coding sequences, T cells transduced with the above TCRs, and their uses in preventing and treating PRAME-related diseases. Background Art
[0002] TCR (T cell receptor, TCR) is generally expressed specifically on the surface of T cells in the form of heterodimers. TCR heterodimers bind to multiple different CD3 subunits in a specific ratio in the form of non-covalent bonds to form a TCR-CD3 complex. T cells can be divided into two categories: αβT cells and γδT cells. The corresponding TCR can also be divided into two categories: αβTCR and γδTCR. αβTCR is composed of two chains, α and β, and γδTCR is composed of two chains, γ and δ. The difference between αβTCR and γδTCR lies in the difference in diversity. αβTCR has more diversity and is a molecule that plays a major role in cellular immunity. In peripheral blood, 90%-95% of T cells express αβTCR. Each peptide chain of αβTCR can be divided into a variable region (V region), a constant region (C region), a transmembrane region, and an intracellular region. TCR molecules belong to the immunoglobulin superfamily, and their antigen specificity is determined by the V region sequence; the V region (Vα, Vβ) each has three hypervariable regions CDR1, CDR2, and CDR3, among which CDR3 has the largest variation, which directly determines the antigen binding specificity of TCR (Xu, X., Li, H. & Xu, C. Structural understanding of T cell receptor triggering. Cell Mol Immunol 17, 193-202 (2020).).
[0003] TCR mediates T cell recognition of target cells by recognizing a complex formed by a peptide and a major histocompatibility antigen (MHC). MHC is mainly divided into two types, MHCⅠ and MHCⅡ, which differ greatly in structure and tissue cell expression distribution. MHCⅠ is composed of α chain and β2-microglobulin (B2M) chain, and MHCⅡ is composed of α chain and β chain. MHC molecules load specific peptide molecules during intracellular secretion and transport to the cell membrane, thereby forming a peptide-MHC complex (R. A. Mariuzza, P. Agnihotri and J. Orban. The structural basis of T-cell receptor (TCR) activation: An enduring enigma. J Biol Chem 295 (4); 914-925 (2020)). When TCR recognizes the peptide-MHC complex, the TCR variable region CDR3 directly binds to the antigen peptide, determining the specificity of TCR. TCR can be developed into TCR-T cell therapy or bispecific drugs.
[0004] As a part of the human immune protection mechanism, T cell activation plays an important role in resisting the invasion of pathogenic microorganisms, foreign proteins, environmental harmful molecules, and tumors, hyperplasia and other diseases. T cells express receptor molecules TCR for recognizing short peptide antigens on their surface. These short peptide antigens are combined with major histocompatibility complex (MHC) molecules (also known as human leukocyte antigens (HLA)) and presented by antigen presenting cells (APC) (Davis et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 16, 523-44 (1998)). CD8+T cells are also called cytotoxic T cells, which have TCRs that specifically recognize peptides bound to MHC class 1 molecules. CD8+T cells are usually responsible for discovering and mediating the destruction of diseased cells, including cancerous cells and virus-infected cells.
[0005] TCR-T is an adoptive cell therapy that screens and identifies TCR sequences that can specifically bind to target antigens, and then uses genetic engineering to transfer them into peripheral blood-derived T cells to prepare T cells that can recognize specific targets, called TCR-T cells. TCR bispecific antibodies are bispecific antibodies that combine TCR and anti-CD3 antibodies through molecular design to target tumor antigens and T cells at the same time. Currently, TCR-based therapies are mainly TCR-T cell therapies and TCR bispecific drugs. Due to the specificity of recognition and action mechanisms, TCR can recognize intracellular targets, and the range of target selection has been expanded. However, the targets that can be selected are still limited. Choosing the right target is crucial to the success of TCR therapy.
[0006] PRAME (Protein Preferentially Expressed Antigen in Melanoma) is a protein encoded by the PRAME gene that is highly expressed in human melanoma tumors. As a member of the cancer-testis antigen family, PRAME is only expressed in small amounts and selectively in normal human tissues, but is expressed at high levels in a variety of tumors, such as melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, etc. These characteristics make PRAME an ideal target for tumor targeted therapy. After processing, the PRAME protein has a special polypeptide sequence: SLLQHLIGL, which can be presented to the cell surface by the HLA-A02 molecule. The HLA-A02 complex bound to the PRAME polypeptide can be used as a TCR target to develop TCR-related therapies.
[0007] Therefore, there is an urgent need in the art for TCRs that can recognize PRAME polypeptides. Summary of the invention
[0008] The object of the present invention is to provide a T cell receptor that recognizes tumor-associated antigens, particularly PRAME polypeptide.
[0009] In a first aspect, the present invention provides a T cell receptor (TCR) capable of binding to a SLLQHLIGL polypeptide-HLA-A*02 complex.
[0010] In a preferred embodiment, the TCR comprises a TCR α chain variable domain and a TCR β chain variable domain, and the amino acid sequence of CDR1 of the TCR α chain variable domain is selected from the group consisting of SEQ ID NO: 12, 22, 32;
[0011] The amino acid sequence of CDR2 of the TCR α chain variable domain is selected from the group consisting of SEQ ID NO: 13, 23, 33;
[0012] The amino acid sequence of CDR3 of the TCR α chain variable domain is selected from the group consisting of SEQ ID NO: 14, 24, 34, 42;
[0013] The amino acid sequence of CDR1 of the TCRβ chain variable domain is selected from the group consisting of SEQ ID NO: 17, 27, 37, 45;
[0014] The amino acid sequence of CDR2 of the TCRβ chain variable domain is selected from the group consisting of SEQ ID NO: 18, 28, 38, 46; and / or
[0015] The amino acid sequence of CDR3 of the TCRβ chain variable domain is selected from the following group: SEQ ID NO: 19, 29, 39, 47.
[0016] In a preferred embodiment, the amino acid sequences of CDR1, CDR2 and CDR3 of the TCR alpha chain variable domain are selected from the following combinations: SEQ ID NOs: 12, 13 and 14; SEQ ID NOs: 22, 23 and 24; SEQ ID NOs: 32, 33 and 34; SEQ ID NOs: 22, 23 and 42;
[0017] and / or
[0018] The amino acid sequences of CDR1, CDR2 and CDR3 of the TCR β chain variable domain are selected from the following combinations: SEQ ID NOs: 17, 18 and 19; SEQ ID NOs: 27, 28 and 29; SEQ ID NOs: 37, 38 and 39; SEQ ID NOs: 45, 46 and 47.
[0019] In a preferred embodiment, the amino acid sequences of CDR1, CDR2 and CDR3 of the TCRα chain variable domain and the amino acid sequences of CDR1, CDR2 and CDR3 of the TCRβ chain variable domain are selected from the following combinations:
[0020] SEQ ID NOs: 12, 13 and 14 and SEQ ID NOs: 17, 18 and 19;
[0021] SEQ ID NOs: 22, 23 and 24 and SEQ ID NOs: 27, 28 and 29;
[0022] SEQ ID NOs: 32, 33 and 34 and SEQ ID NOs: 37, 38 and 39;
[0023] SEQ ID NOs: 22, 23 and 42 and SEQ ID NOs: 45, 46 and 47.
[0024] In a preferred embodiment, the TCR comprises a TCR alpha chain variable domain and a TCR beta chain variable domain, the TCR alpha chain variable domain is an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with SEQ ID NO: 11, 21, 31 or 41; and / or the TCR beta chain variable domain is an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with SEQ ID NO: 16, 26, 36 or 44.
[0025] In a preferred embodiment, the amino acid sequence of the TCR α chain variable domain of the TCR is shown in SEQ ID NO: 11, 21, 31 or 41; and / or the amino acid sequence of the TCR β chain variable domain is shown in SEQ ID NO: 16, 26, 36 or 44.
[0026] In a preferred embodiment, the amino acid sequence of the TCR α chain variable domain and the amino acid sequence of the TCR β chain variable domain of the TCR are selected from the following combinations:
[0027] SEQ ID NOs: 11 and 16; SEQ ID NOs: 21 and 26; SEQ ID NOs: 31 and 36; SEQ ID NOs: 41 and 44.
[0028] In a preferred embodiment, the TCR comprises a TCR α chain and a TCR β chain, the TCR α chain being an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with SEQ ID NO: 10, 20, 30 or 40; and / or the TCR β chain variable domain being an amino acid sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with SEQ ID NO: 15, 25, 35 or 43.
[0029] In a preferred embodiment, the α chain amino acid sequence of the TCR is selected from the group consisting of SEQ ID NO: 10, 20, 30 and 40; and / or
[0030] The β chain amino acid sequence of the TCR is selected from the following group: SEQ ID NO:15, 25, 35 and 43.
[0031] In a preferred embodiment, the α chain amino acid sequence and the β chain amino acid sequence of the TCR are selected from the following combinations: SEQ ID NOs: 10 and 15; SEQ ID NOs: 20 and 25; SEQ ID NOs: 30 and 35; SEQ ID NOs: 40 and 43.
[0032] In a preferred embodiment, the TCR is soluble.
[0033] In a preferred embodiment, the TCR is a single-chain TCR.
[0034] In a preferred embodiment, the TCR is composed of an α chain variable domain and a β chain variable domain connected by a peptide linker sequence.
[0035] In a preferred embodiment, the TCR comprises (i) a TCR α chain variable domain and all or part of the TCR α chain constant region excluding the transmembrane domain; and (ii) a TCR β chain variable domain and all or part of the TCR β chain constant region excluding the transmembrane domain.
[0036] In a preferred embodiment, the TCR comprises an α chain variable domain and a β chain variable domain and all or part of the β chain constant domain excluding the transmembrane domain, but does not comprise an α chain constant domain, and the α chain variable domain of the TCR forms a heterodimer with the β chain.
[0037] In a preferred embodiment, a conjugate is bound to the C- or N-terminus of the α chain and / or β chain of the TCR.
[0038] In a preferred embodiment, the conjugate that binds to the T cell receptor is a detectable marker, a therapeutic agent, a PK modifying moiety, or a combination of any of these substances; preferably, the therapeutic agent is an anti-CD3 antibody.
[0039] In a second aspect, the present invention provides a multivalent TCR complex comprising at least two TCR molecules, wherein at least one TCR molecule is the TCR described in the first aspect.
[0040] In a third aspect, the present invention provides an isolated nucleic acid molecule encoding the TCR described in the first aspect.
[0041] In a fourth aspect, the present invention provides a vector, wherein the vector contains the nucleic acid molecule described in the third aspect; preferably, the vector is a viral vector; more preferably, the vector is a lentiviral vector.
[0042] In a fifth aspect, the present invention provides an isolated host cell, wherein the host cell contains the vector described in the fourth aspect or the exogenous nucleic acid molecule described in the third aspect integrated into the genome.
[0043] In a sixth aspect, the present invention provides a cell, wherein the cell expresses the TCR described in the first aspect on its surface.
[0044] In a preferred embodiment, the cell is transduced with the nucleic acid molecule described in the fourth aspect or the vector described in the fifth aspect.
[0045] In a preferred embodiment, the cell is a T cell, a NK cell, a NKT cell or a stem cell.
[0046] In a preferred embodiment, the cells co-express the CD8 molecule.
[0047] In a preferred embodiment, the CD8 molecule is a human CD8 molecule.
[0048] In a preferred embodiment, the human CD8 molecule is a human CD8a molecule.
[0049] In a preferred embodiment, the human CD8a molecule has the sequence shown in SEQ ID NO:53.
[0050] In the seventh aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the TCR described in the first aspect, the TCR complex described in the second aspect, the nucleic acid molecule described in the third aspect, the vector described in the fourth aspect, or the cell described in the sixth aspect.
[0051] In an eighth aspect, the present invention provides a use of the T cell receptor described in the first aspect, the TCR complex described in the second aspect, or the cell described in the sixth aspect for preparing a drug for treating tumors.
[0052] In a preferred embodiment, the tumor is a PRAME-associated tumor.
[0053] In a preferred embodiment, the tumor is a tumor that specifically expresses the complete or partial tumor antigen PRAME.
[0054] In a preferred embodiment, the tumor is a tumor that specifically expresses the SLLQHLIGL peptide segment.
[0055] In a preferred embodiment, the tumor is melanoma, non-small cell lung cancer, ovarian cancer, or breast cancer.
[0056] In a preferred embodiment, the tumor is non-small cell lung cancer.
[0057] In a ninth aspect, the present invention provides the T cell receptor of the first aspect, the TCR complex of the second aspect, or the cell of the sixth aspect for use as a drug for treating tumors.
[0058] In a preferred embodiment, the tumor is a PRAME-associated tumor.
[0059] In a preferred embodiment, the tumor is a tumor that specifically expresses the complete or partial tumor antigen PRAME.
[0060] In a preferred embodiment, the tumor is a tumor that specifically expresses the SLLQHLIGL peptide segment.
[0061] In a preferred embodiment, the tumor is melanoma, non-small cell lung cancer, ovarian cancer, or breast cancer.
[0062] In a preferred embodiment, the tumor is non-small cell lung cancer.
[0063] In the tenth aspect, the present invention provides a method for treating tumors, comprising administering a therapeutically effective amount of the T cell receptor described in the first aspect, the TCR complex described in the second aspect, or the cell described in the fifth aspect, or the pharmaceutical composition described in the sixth aspect to a subject in need of treatment.
[0064] In a preferred embodiment, the tumor is a PRAME-associated tumor.
[0065] In a preferred embodiment, the tumor is a tumor that specifically expresses the complete or partial tumor antigen PRAME.
[0066] In a preferred embodiment, the tumor is a tumor that specifically expresses the SLLQHLIGL peptide segment.
[0067] In a preferred embodiment, the tumor is melanoma, non-small cell lung cancer, ovarian cancer, or breast cancer.
[0068] In a preferred embodiment, the tumor is non-small cell lung cancer.
[0069] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 It shows the affinity level of the TCR molecules screened by the present invention to the target on the surface of the reporter gene cells;
[0071] Figure 2 It shows the activation effect of T2 cells loaded with target polypeptide on cells expressing the TCR molecule reporter gene of the present invention;
[0072] Figure 3It shows the activation effect of T2 cells loaded with different concentrations of target polypeptide on cells expressing the TCR molecule reporter gene of the present invention;
[0073] Figure 4 This shows the specificity of the TCR molecule of the present invention in binding to the target;
[0074] Figure 5 The expression efficiency of the TCR molecule of the present invention on primary T cells is shown;
[0075] Figure 6 The killing effect of candidate TCR-T on target cells under different effector-target ratios was shown;
[0076] Figure 7 It is shown that target cells specifically activate TCR-T cells carrying the TCR sequence of the present invention and release cytokines;
[0077] Figure 8 The results of in vivo animal efficacy evaluation of candidate TCR-T cells are shown;
[0078] Fig. 9 The results of the test of the killing ability of different groups of T cells on tumor cells are shown, where E: effector; T: target;
[0079] Fig.10 The results of the cytokine release ability test of T cells in different groups are shown. DETAILED DESCRIPTION
[0080] After extensive and in-depth research, the inventors unexpectedly found a TCR that can specifically bind to the PRAME-derived polypeptide SLLQHLIGL (SEQID NO: 1), and the peptide SLLQHLIGL is presented to the cell surface by the HLA-A02 molecule. The present invention also provides a nucleic acid molecule encoding the TCR and a vector containing the nucleic acid molecule. In addition, the present invention also provides a cell transducing the TCR of the present invention. The present invention was completed on this basis.
[0081] Definition of terms
[0082] The terms used herein have the meanings generally understood by those skilled in the art. For a clear understanding of the present invention, some terms are defined as follows.
[0083] MHC molecules
[0084] MHC molecules are proteins of the immunoglobulin superfamily and can be either class I or class II MHC molecules. Therefore, they are specific for antigen presentation. Different individuals have different MHCs that can present different short peptides in a protein antigen to the surface of their respective APC cells. Human MHC is usually called HLA gene or HLA complex.
[0085] SLLQHLIGL peptide
[0086] The SLLQHLIGL peptide of the present invention is a polypeptide sequence derived from the tumor PRAME. The peptide is presented to the cell surface by the HLA-A02 molecule. Therefore, the SLLQHLIGL polypeptide-HLA-A*02 complex provides an ideal target for TCR-T immunotherapy of PRAME-related tumors. The tumor is a PRAME-related tumor.
[0087] In a preferred embodiment, the tumor is a tumor that specifically expresses the complete or partial tumor antigen PRAME.
[0088] T cell receptor
[0089] The T cell receptor used herein has the meaning generally understood by those skilled in the art. It is the only receptor for specific antigenic peptides presented on the major histocompatibility complex (MHC). In the immune system, the binding of the antigen-specific TCR to the pMHC complex triggers direct physical contact between T cells and antigen presenting cells (APCs), and then other cell membrane surface molecules of both T cells and APCs interact, which causes a series of subsequent cell signaling and other physiological reactions, so that T cells with different antigen specificities exert immune effects on their target cells.
[0090] TCR is a glycoprotein on the cell membrane surface that exists in the form of a heterodimer of α chain / β chain or γ chain / δ chain. In 95% of T cells, TCR heterodimers are composed of α and β chains, while 5% of T cells have TCRs composed of γ and δ chains. Natural αβ heterodimeric TCR has α chain and β chain, which constitute the subunits of αβ heterodimeric TCR. Broadly speaking, each α and β chain contains a variable region, a connecting region and a constant region. The β chain usually also contains a short variable region between the variable region and the connecting region, but the variable region is often regarded as part of the connecting region. Each variable region contains three CDRs (complementarity determining regions), CDR1, CDR2 and CDR3, embedded in the framework region. The CDR region determines the binding of TCR to the pMHC complex, among which CDR3 is recombined by the variable region and the connecting region and is called the hypervariable region. The α and β chains of TCR are generally considered to have two "domains" each, namely the variable domain and the constant domain. The variable domain is composed of a connected variable region and a connecting region. The sequence of the TCR constant domain can be found in the public database of the International Immunogenetics Information System (IMGT), such as the constant domain sequence of the TCR molecule α chain is "TRAC*01", and the constant domain sequence of the TCR molecule β chain is "TRBC1*01" or "TRBC2*01". In addition, the α and β chains of TCR also contain transmembrane regions and cytoplasmic regions, and the cytoplasmic region is very short.
[0091] In the present invention, the terms "polypeptide of the present invention", "TCR of the present invention" and "T cell receptor of the present invention" are used interchangeably.
[0092] During antigen processing, the antigen is degraded in the cell and then carried to the cell surface by MHC molecules. The T cell receptor can recognize the peptide-MHC complex on the surface of the antigen presenting cell. Therefore, the present invention provides a TCR molecule that can bind to the SLLQHLIGL polypeptide-HLA-A*02 complex. Preferably, the TCR molecule is isolated or purified. The α and β chains of the TCR each have 3 complementary determining regions (CDRs).
[0093] In a preferred embodiment of the present invention, the amino acid sequence of CDR1 of the TCRα chain variable domain is selected from the group consisting of SEQ ID NO: 12, 22, 32; the amino acid sequence of CDR2 of the TCRα chain variable domain is selected from the group consisting of SEQ ID NO: 13, 23, 33; the amino acid sequence of CDR3 of the TCRα chain variable domain is selected from the group consisting of SEQ ID NO: 14, 24, 34, 42; the amino acid sequence of CDR1 of the TCRβ chain variable domain is selected from the group consisting of SEQ ID NO: 17, 27, 37, 45; the amino acid sequence of CDR2 of the TCRβ chain variable domain is selected from the group consisting of SEQ ID NO: 18, 28, 38, 46; and / or the amino acid sequence of CDR3 of the TCRβ chain variable domain is selected from the group consisting of SEQ ID NO: 19, 29, 39, 47.
[0094] The CDR region amino acid sequence of the present invention described above can be embedded into any suitable framework structure to prepare a chimeric TCR. As long as the framework structure is compatible with the CDR region of the TCR of the present invention, a person skilled in the art can design or synthesize a TCR molecule with corresponding functions based on the CDR region disclosed in the present invention. Therefore, the TCR molecule of the present invention refers to a TCR molecule comprising the above-mentioned α and / or β chain CDR region sequence and any suitable framework structure. The TCR α chain variable domain of the present invention is an amino acid sequence having at least 90%, preferably 95%, and more preferably 98% sequence identity with SEQ ID NO: 11, 21, 31 or 41; and / or the TCR β chain variable domain of the present invention is an amino acid sequence having at least 90%, preferably 95%, and more preferably 98% sequence identity with SEQ ID NO: 16, 26, 36 or 44.
[0095] In a preferred example of the present invention, the TCR molecule of the present invention is a heterodimer consisting of α and β chains. Specifically, on the one hand, the α chain of the heterodimeric TCR molecule comprises a variable domain and a constant domain, and the α chain variable domain amino acid sequence comprises CDR1, CDR2 and CDR3 of the above-mentioned α chain. Preferably, the TCR molecule comprises an α chain variable domain amino acid sequence of SEQ ID NO: 11, 21, 31 or 41. On the other hand, the β chain of the heterodimeric TCR molecule comprises a variable domain and a constant domain, and the β chain variable domain amino acid sequence comprises CDR1, CDR2 and CDR3 of the above-mentioned β chain. Preferably, the TCR molecule comprises a β chain variable domain amino acid sequence of SEQ ID NO: 16, 26, 36 or 44.
[0096] In a preferred embodiment of the present invention, the TCR molecule of the present invention is a single-chain TCR molecule composed of part or all of the α chain and / or part or all of the β chain. The description of the single-chain TCR molecule can refer to the document Chung et al (1994) Proc. Natl. Acad. Sci. USA 91, 12654-12658. According to the document, those skilled in the art can easily construct a single-chain TCR molecule comprising the CDRs region of the present invention. Specifically, the single-chain TCR molecule comprises Vα, Vβ and Cβ, preferably connected in the order from N-terminus to C-terminus.
[0097] The α chain variable domain amino acid sequence of the single-chain TCR molecule comprises the CDR1, CDR2 and CDR3 of the above-mentioned α chain. Preferably, the single-chain TCR molecule comprises the α chain variable domain amino acid sequence SEQ ID NO: 11, 21, 31 or 41. The β chain variable domain amino acid sequence of the single-chain TCR molecule comprises the CDR1, CDR2 and CDR3 of the above-mentioned β chain. Preferably, the single-chain TCR molecule comprises the β chain variable domain amino acid sequence SEQ ID NO: 16, 26, 36 or 44.
[0098] In a preferred embodiment of the present invention, the constant domain of the TCR molecule of the present invention is a human constant domain. Those skilled in the art know or can obtain the constant domain amino acid sequence of a person by consulting relevant books or the public database of IMGT (International Immunogenetics Information System). For example, the constant domain sequence of the α chain of the TCR molecule of the present invention can be "TRAC*01", and the constant domain sequence of the β chain of the TCR molecule can be "TRBC1*01" or "TRBC2*01". The 53rd position of the amino acid sequence given in TRAC*01 of IMGT is Arg, which is represented herein as: Arg53 of TRAC*01 exon 1, and the rest are analogous. Preferably, the amino acid sequence of the α chain of the TCR molecule of the present invention is SEQ ID NO: 10, 20, 30 and 40, and / or the amino acid sequence of the β chain is SEQ ID NO: 15, 25, 35 and 43.
[0099] The naturally occurring TCR is a membrane protein that is stabilized by its transmembrane region. Just like immunoglobulins (antibodies) as antigen recognition molecules, TCR can also be developed for diagnosis and treatment, and soluble TCR molecules need to be obtained at this time. Soluble TCR molecules do not include their transmembrane regions. Soluble TCR has a wide range of uses. It can not only be used to study the interaction between TCR and pMHC, but also be used as a diagnostic tool for detecting infection or as a marker for autoimmune diseases. Similarly, soluble TCR can be used to deliver therapeutic agents (such as cytotoxic compounds or immunostimulatory compounds) to cells presenting specific antigens. In addition, soluble TCR can also be combined with other molecules (such as anti-CD3 antibodies) to redirect T cells, so that they target cells presenting specific antigens. The TCR molecules of the present invention are all soluble, thereby providing more selectivity for the development of TCR-T cell therapy or TCR protein drugs.
[0100] To obtain a soluble TCR, the transmembrane region of the TCR can be removed. Preferably, such a TCR may include (i) all or part of the TCR α chain except its transmembrane domain, and (ii) all or part of the TCR β chain except its transmembrane domain, wherein (i) and (ii) both include the variable domain of the TCR chain and at least a portion of the constant domain, and the α chain and the β chain form a heterodimer. More preferably, such a TCR may include an α chain variable domain and a β chain variable domain and all or part of the β chain constant domain except the transmembrane domain, but it does not include an α chain constant domain, and the α chain variable domain of the TCR forms a heterodimer with the β chain.
[0101] The TCR of the present invention can be a stable soluble single-chain TCR composed of a flexible peptide chain connecting the variable domains of the α and β chains of the TCR. It should be noted that the flexible peptide chain in the present invention can be any peptide chain suitable for connecting the variable domains of the α and β chains of the TCR.
[0102] The TCR of the present invention can also be provided in the form of a multivalent complex. The multivalent TCR complex of the present invention comprises a polymer formed by combining two, three, four or more TCRs of the present invention, such as a tetramerization domain of p53 can be used to produce a tetramer, or a complex formed by combining multiple TCRs of the present invention with another molecule. The TCR complex of the present invention can be used to track or target cells presenting specific antigens in vitro or in vivo, and can also be used to produce intermediates of other multivalent TCR complexes with such applications.
[0103] The TCR of the present invention can be used alone or can be covalently or otherwise bound to a conjugate, preferably covalently bound. The conjugate includes a detectable marker (for diagnostic purposes, wherein the TCR is used to detect the presence of cells presenting the GLSPTVWLSV polypeptide-HLA-A*02 complex), a therapeutic agent, a PK (protein kinase) modifying portion, or any combination of these substances.
[0104] Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing a detectable product.
[0105] Therapeutic agents that can be combined or coupled to the TCR of the present invention include, but are not limited to: 1. Radionuclides (Koppe et al., 2005, Cancer metastasis reviews 24, 539); 2. Biotoxins (Chaudhary et al., 1989, Nature 339, 394; Epel et al., 2002, Cancer Immunology and Immunotherapy 51, 565); 3. Cytokines, such as IL-2, etc. (Gillies et al., 1992, PNAS 89, 1428; Card et al., 2004, Cancer Immunology and Immunotherapy 53, 345; Halin et al., 2003, Cancer Research 63, 3202); 4. Antibody Fc fragments (Mosquera et al., 2005, The Journal Of Immunology 174, 4381); 5. Antibody scFv fragments (Zhu et al., 1995, International Journal of Cancer 62,319); 6. Gold nanoparticles / nanorods (Lapotko et al., 2005, Cancer letters 239,36; Huang et al., 2006, Journal of the American Chemical Society 128,2115); 7. Virus particles (Peng et al., 2004, Gene therapy 11,1234); 8. Liposomes (Mamot et al., 2005, Cancer research 65,11631); 9. Nanomagnetic particles; 10. Prodrug activating enzymes (e.g., DT-diaphorase (DTD) or biphenyl hydrolase-like protein (BPHL)); 11. Chemotherapeutic agents (e.g., cisplatin) or any form of nanoparticles, etc.
[0106] In addition, the TCR of the present invention can also be a hybrid TCR comprising sequences derived from more than one species. For example, studies have shown that murine TCR can be expressed more effectively in human T cells than human TCR. Therefore, the TCR of the present invention can comprise human variable domains and mouse constant domains. The drawback of this method is that an immune response may be induced. Therefore, when it is used for adoptive T cell therapy, there should be a regulatory scheme to perform immunosuppression to allow the implantation of murine T cells expressing murine T cells.
[0107] It should be understood that the amino acid names herein are represented by single letters or three letters in the internationally accepted manner, and the correspondence between single letters and three letters of the amino acid names is as follows: Ala (A), Arg (R), Asn (N), Asp (D), Cys (C), Gln (Q), Glu (E), Gly (G), His (H), Ile (I), Leu (L), Lys (K), Met (M), Phe (F), Pro (P), Ser (S), Thr (T), Trp (W), Tyr (Y), Val (V).
[0108] Immunoconjugates
[0109] The term "immunoconjugate" used herein has the meaning generally understood by those skilled in the art. The term refers to an artificially synthesized molecule comprising different parts (usually proteins) coupled by chemical means and having an immunological effect.
[0110] Nucleic acid molecules
[0111] The present invention provides nucleic acid molecules encoding the TCR of the present invention or a portion thereof, which portion may be one or more CDRs, the variable domains of the α and / or β chains, and the α chain and / or β chain.
[0112] The nucleotide sequence of the nucleic acid molecule of the present invention can be single-stranded or double-stranded, the nucleic acid molecule can be RNA or DNA, and can contain or not contain introns. Preferably, the nucleotide sequence of the nucleic acid molecule of the present invention does not contain introns but can encode the polypeptide of the present invention.
[0113] It should be understood that due to the degeneracy of the genetic code, different nucleotide sequences can encode the same polypeptide. Therefore, the nucleic acid sequence encoding the TCR of the present invention can be the same as the nucleic acid sequence shown in the present invention or a degenerate variant.
[0114] The nucleotide sequence can be codon optimized. Different cells differ in the use of specific codons, and the codons in the sequence can be changed to increase expression according to the type of cell. Codon usage tables for mammalian cells and a variety of other organisms are well known to those skilled in the art.
[0115] The full-length sequence of the nucleic acid molecule of the present invention or its fragment can usually be obtained by, but not limited to, PCR amplification, recombination or artificial synthesis. At present, the DNA sequence encoding the TCR of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. The DNA can be a coding strand or a non-coding strand.
[0116] Carrier
[0117] The present invention also relates to vectors comprising the nucleic acid molecules of the present invention, including expression vectors, i.e. constructs capable of in vivo or in vitro expression. Commonly used vectors include bacterial plasmids, bacteriophages, and animal and plant viruses.
[0118] Viral delivery systems include, but are not limited to, adenoviral vectors, adeno-associated viral (AAV) vectors, herpes viral vectors, retroviral vectors, lentiviral vectors, baculoviral vectors.
[0119] Preferably, the vector can transfer the nucleotide of the present invention into cells, such as T cells, so that the cells express HBV antigen-specific TCR. Ideally, the vector should be able to be expressed at a high level in T cells.
[0120] cell
[0121] The present invention also relates to a host cell produced by genetic engineering using the vector or coding sequence of the present invention. The host cell contains the vector of the present invention or has the nucleic acid molecule of the present invention integrated into the chromosome. The host cell is selected from: prokaryotic cells and eukaryotic cells, such as Escherichia coli, yeast cells, CHO cells, etc.
[0122] In addition, the present invention also includes cells expressing the separation of the TCR of the present invention, which may be, but are not limited to, T cells, NK cells, NKT cells, stem cells, and particularly T cells. The T cell may be derived from a T cell separated from a subject, or may be a mixed cell population separated from a subject, such as a part of a peripheral blood lymphocyte (PBL) population. As, the cell may be separated from peripheral blood mononuclear cells (PBMC), may be CD4+ helper T cells or CD8+ cytotoxic T cells. The cell may be in a mixed population of CD4+ helper T cells / CD8+ cytotoxic T cells. Generally, the cell may be activated with an antibody (e.g., an anti-CD3 or anti-CD28 antibody) so that they can be more easily transfected, for example, transfected with a vector comprising a nucleotide sequence encoding the TCR molecule of the present invention.
[0123] Alternatively, the cells of the present invention may also be or be derived from stem cells, such as hematopoietic stem cells (HSC). Gene transfer to HSC will not result in TCR expression on the cell surface, because CD3 molecules are not expressed on the stem cell surface. However, when stem cells differentiate into lymphoid precursors that migrate to the thymus, the expression of CD3 molecules will initiate the expression of the introduced TCR molecules on the surface of thymocytes.
[0124] There are many methods suitable for transfecting T cells with DNA or RNA encoding the TCR of the present invention (e.g., Robbins et al., (2008) J. Immunol. 180: 6116-6131). T cells expressing the TCR of the present invention can be used for adoptive immunotherapy. Those skilled in the art will be aware of many suitable methods for adoptive therapy (e.g., Rosenberg et al., (2008) Nat Rev Cancer 8(4): 299-308).
[0125] In order to improve the biological activity of the TCR molecule of the present invention in CD4-positive T cells, the cells expressing the TCR of the present invention can further co-express CD8 molecules, such as human CD8 molecules, preferably human CD8a molecules.
[0126] Treatment
[0127] Treatment can be performed by isolating T cells from patients or volunteers infected with HBV virus-induced HCC or chronic hepatitis, introducing the TCR of the present invention into the above-mentioned T cells, and then returning these genetically modified cells to the patient. Therefore, the present invention provides a method for treating HBV-related diseases, comprising transferring separated T cells expressing the TCR of the present invention, preferably, the T cells are derived from the patient himself, into the patient. Generally, it includes (1) isolating the patient's T cells, (2) transducing T cells in vitro with the nucleic acid molecules of the present invention or nucleic acid molecules capable of encoding the TCR molecules of the present invention, and (3) transferring the genetically modified T cells into the patient. The number of cells separated, transfected and returned can be determined by the physician.
[0128] Advantages of the present invention:
[0129] (1) The TCR of the present invention can specifically bind to the complex composed of the GLSPTVWLSV peptide segment and HLA-A*02, and the effector cells transduced with the TCR of the present invention can be specifically activated;
[0130] (2) The effector cells transduced with the TCR of the present invention can specifically kill GLSPTVWLSV peptide-positive target cells;
[0131] (3) after stimulation by target cells, the effector cells transduced with the TCR of the present invention are able to secrete a large amount of cytokines; and
[0132] (4) The present invention provides TCR molecules with different levels of affinity activity with the target pMHC complex, and all of them are soluble, which can provide more selectivity for the development of TCR-T cell therapy or TCR protein drugs.
[0133] The following specific examples further illustrate the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions, such as the conditions described in Sambrook and Russell et al., (Molecular Cloning: A Laboratory Manual (Molecular Cloning-A Laboratory Manual) (3rd Edition) (2001) CSHL Press), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. The experimental materials and reagents used in the following examples can be obtained from commercial channels unless otherwise stated.
[0134] Example:
[0135] Example 1: Obtaining candidate TCR molecules
[0136] 1.1 Antigen-specific T cell activation
[0137] Peripheral blood T cells are activated by in vitro activation of healthy donor PBMCs (Peripheral blood mononuclear cells, Miaoshun (Shanghai) Biotechnology Co., Ltd.) or by using a peptide immunization method or a peptide-loaded DCs immunization method, and then the T cells are stained with a fluorescently labeled polymer (Tetramer, etc.), and the T cells that can be stained by the polymer are sorted using a flow cytometer. This group of T cells may be T cells activated by antigen specificity. The polypeptide sequence used in this study is: SLLQHLIGL (SEQ ID NO: 1). The polypeptide sequence used in this example is derived from the PRAME protein.
[0138] 1.2 TCR sequence acquisition
[0139] TCR screening and cloning were performed with reference to published literature (Paria BC, Levin N, Lowery FJ, et al. Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells. Journal of Immunotherapy (Hagerstown, Md.: 1997). 2021 Jan; 44 (1): 1-8. Pai, JA, Satpathy, AT High-throughput and single-cell T cell receptor sequencing technologies. Nat Methods 18, 881-892 (2021). De Simone M, Rossetti G and Pagani M (2018) Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges. Front. Immunol. 9: 1638. doi: 10.3389 / fimmu.2018.01638). The TCR clones obtained by screening were named: TCR-01, TCR-02, TCR-03 and TCR-04. The full-length amino acid sequence of the TCR variable region is shown in Table 1. The variable region subtypes and CDR region sequences of TCR were analyzed through the IMGT website to obtain the sequences of the CDR1 region, CDR2 region and CDR3 region of different TCRs (amino acid sequences are shown in Table 1).
[0140] Table 1. Amino acid sequence listing
[0141]
[0142]
[0143]
[0144] Example 2: Expression of candidate TCR molecules and evaluation of biological functions
[0145] 2.1 Construction of TCR gene vector
[0146] The variable region sequences of the TCR alpha and TCR beta genes cloned in Example 1 were connected to the constant regions of mouse TCR alpha and TCR beta, respectively, to construct the full-length sequences of TCR alpha and TCR beta.
[0147] Then, the paired TCR alpha and TCR beta full-length sequences were connected through the 2A fragment and constructed into the lentiviral vector for lentiviral packaging. The lentivirus was concentrated by high-speed centrifugation and stored in a -80 refrigerator. The basic steps of the experiment are as follows:
[0148] 1) On the first day, HEK-293T cells (purchased from the cell bank of the Chinese Academy of Sciences) were inoculated at a rate of about 1.0×10^7 cells / T175 flask (cultured in 30 mL of culture medium) so that transfection could be performed when the cell density reached 80-90% on the second day.
[0149] 2) The next day, plasmid transfection: Before transfection, the culture medium needs to be replaced with DMEM culture medium with 10% FBS but without dual antibodies. First, prepare the plasmid complex separately: add the following plasmids into 1.5 ml Opti-MEM (Thermo Fisher Scientific; 31985-070) and mix well: 18 μg of psPAX2 plasmid (Addgene; Catalog No.: 12260), 9 μg of pMD2.G plasmid (Addgene; Catalog No.: 12259), 18 μg of viral vector plasmid. The lentiviral vector plasmids carrying TCR-01, TCR-02, TCR-03 and TCR-04 genes are named: lenti-TCR-01, lenti-TCR-02, lenti-TCR-03 and lenti-TCR-04, respectively. Prepare the transfection reagent complex: add 45 μL (3 mg / mL) PEI (polysciences: 24765) to 1.5 mL Opti-MEM according to the mass ratio of plasmid to PEI of 1:3, mix well, and let stand at room temperature for 5 minutes; then add the transfection reagent complex dropwise to the plasmid complex, mix well, and let stand for 20 minutes. Finally, slowly drip the transfection complex into the 293T cell culture flask, mix gently, and place in a cell culture incubator at 37°C with 5% CO2 for culture.
[0150] 3) On the fifth day, collect the virus: collect the culture medium supernatant 72 hours after transfection, and centrifuge at 2000rpm for 10 minutes to remove cell debris. Use a 0.45μM filter membrane to filter the supernatant, and transfer the filtrate to a dedicated centrifuge tube for balancing. Use an ultracentrifuge to ultracentrifuge at 25000rpm for 2 hours. After pouring out the supernatant, resuspend the lentivirus in X-VIVO-15 culture medium, and store the lentivirus in a -80℃ ultra-low temperature refrigerator after aliquoting. According to this process, prepare lentivirus containing TCR-01, TCR-02, TCR-03 and TCR-04 genes respectively.
[0151] 2.2 Preparation of TCR-reporter cell lines.
[0152] The reporter gene cell line used in this study is a Jurkat cell that knocks out the endogenous TCRα and β genes, carries the NFAT promoter and luciferase gene, and expresses the CD8a and CD8b genes, named Jurkat-TCRKO-031 (Smith-Garvin JEet al., 2009. T Cell Activation. Ann. Rev. Immunol. 27: 591-619). The lentivirus carrying the candidate TCR gene is added to the reporter gene cells respectively. After 2-3 days, the expression of TCR is detected by polymer staining and flow cytometry. The basic steps are as follows:
[0153] 1) Synthesize HLA-A2 restricted PRAME target peptide (Nanjing GenScript Biotechnology Co., Ltd., SEQ ID No.: 1), and prepare PE fluorescein-coupled MHCⅠ-peptide complex multimer Dextramer according to the instructions of the kit (Immudex, catalog number: U-LX02) for detecting TCR that specifically recognizes the target peptide;
[0154] 2) Take Jurkat-TCRKO-031 cells grown to the logarithmic phase and add 5×10 5 / well were inoculated into 6-well plates, and the volume of each well was supplemented with culture medium to 2 mL;
[0155] 3) Take 100 μL of packaged lentiviral solution, add it dropwise into the well plate, and shake gently to mix the virus solution and culture medium thoroughly;
[0156] 4) The well plate was placed in a 37°C, 5% CO2 incubator for 48 h, and the tool cells transfected with TCR-01, TCR-02, TCR-03 and TCR-04 genes were named TCR-P1, TCR-P2, TCR-P3 and TCR-P4 respectively; the NTD group was untransfected cells, serving as negative control cells;
[0157] 5) After 48 h, take out 200 μL of cell suspension, collect cells by centrifugation, and wash the cells once with FACS buffer (PBS containing 2% FBS);
[0158] 6) Resuspend the cells with 100 μL FACS buffer, add 1 μL APC anti-huam CD3 and 2 μL Dextramer prepared above to each tube, mix well and incubate at 4°C for 30 minutes;
[0159] 7) After incubation, wash the cells twice with FACS buffer and collect the cells by centrifugation;
[0160] 8) Resuspend the cells in 100 μL FACS buffer and detect the proportion of CD3 and Dextramer positive cell populations on a flow cytometer. The flow cytometric results are as follows: Figure 1 shown.
[0161] The results showed that the four TCR sequences screened by the present invention can be integrated into the cell genome and expressed on the cell surface by lentiviral transfection, and the transfection positive rate is high; Dextramer staining results show that the four TCR molecules can bind to Dextramer, among which TCR-P1 and TCR-P2 have higher binding levels (>50%); while TCR-P3 and TCR-P4 have only weak binding.
[0162] 2.3 Evaluation of T cell activation effect
[0163] Use T2 cells as target cells, load different concentrations of peptides, activate reporter cells, and calculate EC50 values. The basic steps are as follows:
[0164] 1) Take T2 cells grown to the logarithmic phase and resuspend them in complete medium to 2×10 6 / mL;
[0165] 2) Use complete culture medium to dilute the target peptide to 60 μM, mix the diluted peptide solution and cell suspension at a volume ratio of 1:1, and incubate at 37°C incubator for 1-2 hours to load the peptide onto the T2 cell surface;
[0166] 3) After incubation, wash away excess peptides with culture medium, collect cells by centrifugation, and resuspend cells to 2×10 5 / mL, T2 cells loaded with different concentrations of peptides were inoculated into 96-well white opaque cell culture plates at 50 μL / well;
[0167] 4) Take the TCR-P1, TCR-P2, TCR-P3 and TCR-P4 cells expressing the TCR molecules of the present invention prepared in Example 2, and the negative control cell NTD group, and adjust the cell density to 1×10 6 / mL, add 50 μL / well to a 96-well plate, place on a microplate shaker to mix evenly, and then transfer the cells to a 37°C incubator for 4-6 hours;
[0168] 5) After the incubation, D-luciferin reaction substrate (purchased from Thermo Fisher Scientific, catalog number L2912) was added to the culture plate at 100 μL / well, and reacted at room temperature in the dark for 10 minutes. Then, the fluorescence signal value (RLU) was detected using an ELISA reader (Thermo Fisher Scientific, Varioskan.LUX). The results are as follows: Figure 2 shown.
[0169] The results showed that Jurkat-TCRKO-031 cells expressing the four TCR molecules shown in the present invention can be activated by T2 cells loaded with target polypeptides and express fluorescent signals, among which TCR-P1 and TCR-P2 have higher activation effects, which are equivalent to the positive control level, showing better biological activity; TCR-P3 and TCR-P4 molecules have lower activation levels and only express weak fluorescent signals.
[0170] 2.4 Evaluation of the biological activity of candidate TCR molecules
[0171] In order to more comprehensively evaluate the biological activity of candidate TCR molecules, this example uses T2 cells loaded with different concentrations of peptides as target cells, activates reporter cells, fits the dose curve, and calculates the EC50 value. The basic steps are as follows:
[0172] 1) Take T2 cells grown to the logarithmic phase and resuspend them in complete medium to 2×10 6 / mL, the cell suspension was inoculated into a 96-well U-bottom deep-well plate at 100 μL / well;
[0173] 2) Use complete medium to dilute the target peptide, with a starting concentration of 50 μM, 4-fold gradient to 10 concentration points, and add the diluted peptide solution to the cells in step 1 at 100 μL / well, mix well, and incubate in a 37°C incubator for 1-2 hours to load the peptide onto the T2 cell surface;
[0174] 3) After the incubation is completed, the excess polypeptide is washed away with culture medium, the cells are collected by centrifugation, 0.9 mL of culture medium is added to each well to resuspend the cells, and T2 cells loaded with different concentrations of polypeptides are inoculated into a 96-well white opaque cell culture plate at a rate of 50 μL / well;
[0175] 4) Take the TCR-P1, TCR-P2, TCR-P3 and TCR-P4 cells expressing the TCR molecules of the present invention prepared in Example 2, and adjust the cell density to 1×10 6 / mL, add 50 μL / well to a 96-well plate (with untransfected Jurkat-TCRKO-031 cells as a negative control), place on a microplate shaker to mix evenly, and then transfer the cells to a 37°C incubator for incubation for 4-6 hours;
[0176] 5) After the incubation, D-luciferin substrate (purchased from Thermo Fisher Scientific, catalog number L2912) was added to the culture plate at 100 μL / well, reacted at room temperature in the dark for 10 minutes, and then the fluorescence signal value (RLU) was detected using a microplate reader (Thermo Fisher Scientific, Varioskan.LUX);
[0177] 6) Graphpad Prism software was used for data analysis, dose-dependent curve fitting, and EC50 value calculation. Figure 3 shown.
[0178] The results showed that the reporter gene cells expressing the four TCR molecules shown in the present invention can be activated by T2 cells loaded with target polypeptides and express fluorescent signals, among which TCR-P1 and TCR-P2 have higher activation signals, with EC50 values of 0.02409 and 0.02163 μM, respectively, and show obvious dose-dependent effects, indicating good biological activity; the activation signals of TCR-P3 and TCR-P4 are weaker and have no dose-dependency, which is presumably caused by their low molecular affinity.
[0179] Example 3: Analysis of off-target effects of candidate TCR molecules
[0180] Referring to the experimental steps of Example 2.4, peptides with similar sequences (Nanjing GenScript Biotechnology Co., Ltd., SEQ ID No.: 2-9) were used as potential off-target peptides, and T2 cells loaded with different off-target peptides were used as target cells. The peptide sequences are shown in Table 2. Jurkat-TCRKO-031 expressing the TCR molecules described in this patent were used as effector cells, and luciferase activity was detected after co-culture. The basic steps are as follows:
[0181] 1) Dissolve the off-target peptides with DMSO to a 10 mM stock solution, take 3 μL of the peptide stock solution and add it to 1 mL of complete culture medium (RPMI 1640 culture medium containing 10% FBS) to make the working concentration 30 μM;
[0182] 2) Take T2 cells with good growth status, collect the cells by centrifugation, and resuspend the cells to 1×10 6 / mL density, and the cell suspension was placed in a cell culture incubator for 1 hour;
[0183] 3) Take the Jurkat-TCRKO-031 cells expressing the candidate TCR prepared in Example 1 and resuspend them in culture medium to 1×10 6 / mL, add the cell suspension to a 96-well white opaque cell culture plate (purchased from Thermo, catalog number 136101) at 50 μL / well;
[0184] 4) The T2 cells loaded with peptides were washed twice with culture medium and then 2×10 5 / mL density resuspend the cells, add T2 cells loaded with different peptides to the corresponding wells at 50 μL / well, use T2 cells without peptide loading as negative control, and T2 cells loaded with PRAME target peptide as positive control;
[0185] 5) Place the well plate on a microplate shaker to shake for 10 minutes to mix the cells, remove the well plate and place it in an incubator for 4-6 hours;
[0186] 6) After the incubation, D-luciferin substrate (purchased from Thermo Fisher Scientific, catalog number L2912) was added to the culture plate at 100 μL / well, reacted at room temperature in the dark for 10 minutes, and then the fluorescence signal value (RLU) was detected using a microplate reader (Thermo Fisher Scientific, Varioskan.LUX);
[0187] 7) Graphpad Prism software was used for data analysis. Figure 4 shown.
[0188] The results showed that the four candidate TCR molecules all showed good specificity and safety, could only be specifically activated by T2 cells presenting the target peptide, and could not recognize the eight off-target peptides, and were worthy of further development.
[0189] Table 2. List of off-target analysis peptide sequences used in the present invention:
[0190] Serial number Peptide name Peptide sequence 1 Target SLLQH 2 OTP-01 LLLAHIIAL 3 OTP-02 ALMYHTITL 4 OTP-03 FLPIHLLGL 5 OTP-04 YLDGHLITT 6 OTP-05 ILAMHLIDV 7 OTP-06 KLYQHEINL 8 OTP-07 SLADRLIGV 9 OTP-08 SLLGHVIRL
[0191] Example 4: Functional evaluation of candidate TCR molecules in primary human T cells
[0192] 4.1 TCR-T cell preparation
[0193] The lentiviral solution carrying the candidate TCR gene prepared in Example 2 was used to infect primary human T cells to prepare TCR-T cells carrying different TCR genes. The TCR-T cells carrying the four TCR clonal T genes were named: TCR-T-01, TCR-T-02, TCR-T-03 and TCR-T-04. Anti-mouse constant region antibodies were used to detect the expression of TCR genes. The specific steps are as follows:
[0194] 1) CD3+ T cells from healthy human peripheral blood (Miaoshun (Shanghai) Biotechnology Co., Ltd.) were resuspended in T cell culture medium containing 300 IU / mL IL-2 to a density of 1×10 6 / mL, add T cell activator CD3 / CD28 magnetic beads (purchased from ACROBiosystems, catalog number: MBS-C001) at a ratio of 1:1 between cells and magnetic beads, mix thoroughly, and then inoculate the cells in a 6-well plate for culture;
[0195] 2) After 48 hours of culture, the cells were aspirated, the magnetic beads were removed by magnetic adsorption, and the cells were collected by centrifugation;
[0196] 3) Resuspend the cells in fresh culture medium and inoculate them into a new 6-well plate, with 5×10 cells per well. 5 cells, added 100 μL of lentiviral solution carrying different TCR genes, and T cells without virus solution were used as negative control NTD, and the cells were placed in the incubator and cultured for 5 days;
[0197] 4) Take 100 μL of cell suspension, collect cells by centrifugation, resuspend cells with 100 μL FACS buffer, add 1 μL APC anti-mouse TCRβ (Biolegend, Cat. No.: 109212) antibody to each tube of cells, mix well, and incubate at 4°C for 30 minutes;
[0198] 5) Wash the cells twice, resuspend the cells in 100 μL FACS buffer, and detect the expression efficiency of TCR on T cells by flow cytometry.
[0199] The results showed that the four TCR molecules of the present invention could be successfully expressed on T cells, with a positive expression rate of 40-80% ( Figure 5 ). The TCR-T cells prepared by the present invention can be used for subsequent biological function evaluation.
[0200] 4.2 Cell killing assay
[0201] The TCR-T cells prepared by the present invention can specifically recognize and kill target cells. This experiment uses four HLA-A2 and PRAME target expression double positive cell lines as target cells, namely non-small cell lung cancer NCI-H1755, ovarian cancer OVCAR-3, melanoma HS695T and osteosarcoma U2OS cell lines; PRAME negative, HLA-A2 positive MCF-7 cells, and PRAME and HLA-A2 negative A549 cells are used as negative cells, and the TCR-T cells prepared in the above examples are co-cultured with target cells to detect the killing effect and evaluate the biological function of TCR-T. The specific steps are as follows:
[0202] 1) preparing a lentiviral solution expressing GFP luciferase according to the method of Example 2.1, and transfecting different target cells with the lentiviral solution to obtain cell lines labeled with luciferase, which were labeled as: NCI-H1755-GFP, OVCAR-3-GFP, HS695T-GFP, U2OS-GFP, MCF-7-GFP and A549-GFP;
[0203] 2) Resuspend different tumor cell lines in culture medium to 2×10 5 / mL, and the tumor cells were inoculated into 96-well flat-bottom opaque cell culture plates at 50 μL / well and temporarily incubated at 37°C;
[0204] 3) Use NTD cells to adjust the positive ratio of the four TCR-T cells to 40%, and resuspend the four TCR-T cells to 3×10 6 / mL, 1×10 6 / mL and 2×10 5 / mL 3 different cell densities (effect-target ratios were 15:1, 5:1 and 1:1, respectively), with NTD cells as negative control, the effector cells of the above different densities were inoculated into 96-well culture plates at 50 μL / well, mixed thoroughly, and incubated in a 37°C incubator for 24 hours;
[0205] 4) Take out the opaque 96-well flat-bottom plate after co-culture, add 100 μL of an equal volume of D-luciferin substrate (Thermo Fisher Scientific: 88293) to the wells, mix well and react in the dark for 10 minutes, and detect the fluorescence intensity in the chemiluminescence mode of the microplate reader. Since luciferase is only expressed in target cells, the remaining luciferase activity in the well is directly related to the number of live target cells. The culture medium is added to the target cells to obtain the maximum luciferase activity as a control, and the target cell apoptosis ratio is calculated by deducting the live cell fluorescence signal value, which is the killing effect of TCR-T cells on target cells. The results are shown in Figure 6 As shown ( Figure 6 A: NCI-H1755-GFP; Figure 6 B: OVCAR-3-GFP; Figure 6 C: HS695T-GFP; Figure 6 D: U2OS-GFP; Figure 6 E: MCF-7-GFP; Figure 6 F: A549-GFP; ).
[0206] The results showed that the four TCR molecules described in the present invention can all mediate T cell killing of three target-positive cells, among which the killing effect on NCI-H1755 cells is the strongest.
[0207] 4.3 Cytokine secretion detection
[0208] In order to further evaluate the specific activation function of target cells, in this example, candidate TCR-T cells were co-cultured with target cells expressing positive and negative targets at a 1:1 effector-target ratio for 24 hours, and the level of IFN-γ cytokine secreted by T cells in the culture supernatant was detected. The specific steps are as follows:
[0209] 1) Take the tumor cells used in Example 4.2, HepG2 cells (target expression negative) and T2 cells, and resuspend them to 2×10 6 / mL, the cell suspension was inoculated into a 96-well U-bottom deep-well plate at 50 μL / well;
[0210] 2) Take the four types of TCR-T cells prepared in Example 4.1 (with untransfected NTD cells as negative control), adjust the transfection positive rate to about 40% with NTD cells, and adjust the cell density to 2×10 6 / mL, add 50 μL / well to a 96-well plate, place on a microplate shaker to mix evenly, and then transfer the cells to a 37°C incubator and incubate for 24 hours;
[0211] 3) After the incubation, 50 μL of culture supernatant was collected and transferred to a new U-bottom 96-well plate. The secretion of IFN-γ cytokines in T cells was detected using an ELISA kit (Thermo Fisher Scientific; Cat. No. 88-7316). Plate preparation and supernatant cytokine detection were performed according to the instructions provided by the kit;
[0212] The results show that ( Figure 7 ), the candidate TCR-T cells can effectively recognize tumor cells with positive target expression, activate TCR-T cells and transmit immune signals, secrete IFN-γ cytokines, among which the biological activity of TCR-T-01 molecule is relatively better.
[0213] Based on the above results, the TCR sequences described in the present invention have good affinity activity and biological functions, among which the antigen binding activity, biological function and specificity of the TCR-01 molecule and the TCR-02 molecule show higher potential, suggesting that they are worthy of further development and application.
[0214] Example 5: In vivo efficacy evaluation in animals
[0215] In this example, the TCR molecules TCR-P1 and TCR-P2 were further evaluated for their in vivo efficacy in mice. Two TCR-T cells were prepared with reference to Example 4: TCR-T-01 and TCR-T-02. T cells that were not transfected with lentivirus were used as control T cells (NTD, no transduction). The human melanoma A375 tumor cell line (ATCC; Product No. CRL-1619) was amplified and cultured under conventional culture conditions, and cells in the logarithmic growth phase were harvested after at least 3 passages. After centrifugation to collect the tumor cells, they were resuspended in 1xPBS to 2.5×10 7 pcs / mL, and matrix gel was added at a ratio of 1:1. Thirty female fully immunodeficient NOG mice (Wei Tong Li Hua Co., Ltd.) were taken. Under sterile conditions, 0.2 mL of A375 tumor cell suspension (5x 10 6 Tumor cells). Seven days after inoculation of tumor cells, the tumor size was measured using a ruler. When the tumor reached 100 mm 3 The mice were randomly divided into groups.
[0216] In this experiment, mice were randomly divided into 4 groups: buffer group, non-transfected control T cell group (NTD), TCR-T-01 group, and TCR-T-02 group, with 5 mice in each group. The prepared T cells of different groups were centrifuged at 1800 rpm for 5 minutes. After resuspending the cells in 1x PBS buffer, the cell density of the test product was adjusted. Animals in each group of the test product were given 1×10 7 Total T cells / cell (about 5×10 6 Transfected TCR-positive cells) were administered by tail vein injection by adjusting the administration volume. After the T cells were reinfused, the experimental group mice were intraperitoneally injected with IL-2 cytokine solution (200,000 IU / mouse) on the same day. The tumor diameter was measured with a vernier caliper twice a week, and the tumor size of the mice was measured and evaluated. The observation was continued for 30 days, and the diet and activity of the mice were also observed. After the experiment, the tumor volume was used as the ordinate and the number of days as the abscissa for plotting.
[0217] The study found that both the TCR-T-01 group and the TCR-T-02 group could eliminate tumors and inhibit tumor growth. From the 20th day, the tumors in the TCR-T-02 group began to grow again. However, the TCR-T-01 group controlled tumor growth well for a long time (see Figure 8 ), showing good anti-tumor effects. Therefore, both TCR-T-01 cells and TCR-T-02 cells showed good in vivo animal efficacy. TCR-T-01 cells completely eliminated tumor cells in mice and well controlled tumor recurrence, so the molecule TCR-P1 can be further developed as a candidate molecule.
[0218] Example 6: Optimization of TCR molecular structure
[0219] The TCR molecules discovered in this study are all CD8-dependent and require the assistance of CD8 molecules to better recognize HLA-A molecules. Therefore, in CD4-positive T cells, the TCR molecules discovered in this study cannot recognize HLA-A molecules very well. CD4-positive T cells can release a large amount of cytokines after activation, thereby increasing the activity of CD8-positive T cells. In order to improve the biological activity of the TCR molecules of the present invention in CD4-positive T cells, this study connected the example TCR molecule (TCR01, with its signal peptide replaced by a human signal peptide, shown in bold) and the human CD8a molecule (Uniprot: P01732) and co-expressed them. The TCR after connecting the CD8a molecule is named: TCR-P1-CD8, and the amino acid sequence is shown in Table 3.
[0220] Table 3. TCR-P1-CD8 molecule amino acid sequence
[0221]
[0222]
[0223] Referring to Example 4, T cells co-expressing CD8 were prepared and named TCR-T-01CD8. Referring to Example 4, experimental groups were designed: three groups of T cells, non-transfected control group (NTD), TCR-T-01 and TCR-T-01CD8. Referring to Example 4, this study evaluated the cell killing ability and cytokine IFN-gamma release ability of the three T cells against the target cell OVCAR3 (cell bank of the Chinese Academy of Sciences). The results of the cell killing ability test are shown in Fig. 9 The results of cytokine release ability test are shown in Fig.10 .
[0224] The results showed that TCR-T cells co-expressing CD8 TCR-T-01CD8 showed better killing ability than TCR-T-01 cells without CD8 expression ( Fig. 9 ). TCR-T cells that co-express CD8a release more IFN-gamma cytokines ( Fig.10 ). The above results suggest that TCR-T cells co-expressing CD8 have better biological activity. TCR co-expressing CD8 can be used as a candidate molecule for further development.
[0225] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A T cell receptor (TCR), wherein the TCR is capable of binding to a SLLQHLIGL polypeptide-HLA-A*02 complex; The amino acid sequence of CDR1 of the TCRα chain variable domain is shown in SEQ ID NO: 12, the amino acid sequence of CDR2 is shown in SEQ ID NO: 13, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 14, and the amino acid sequence of CDR1 of the TCRβ chain variable domain is shown in SEQ ID NO: 17, the amino acid sequence of CDR2 is shown in SEQ ID NO: 18, and the amino acid sequence of CDR3 is shown in SEQ ID NO:
19.
2. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR comprises a TCR α chain variable domain and a TCR β chain variable domain, wherein the TCR α chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 11; and / or the TCR β chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO:
16.
3. The T cell receptor (TCR) according to claim 2, It is characterized in that The amino acid sequence of the TCRα chain variable domain of the TCR is shown in SEQ ID NO: 11; and / or the amino acid sequence of the TCRβ chain variable domain is shown in SEQ ID NO:
16.
4. The T cell receptor (TCR) according to claim 3, It is characterized in that The amino acid sequence of the TCRα chain variable domain of the TCR is shown in SEQ ID NO: 11 and the amino acid sequence of the TCRβ chain variable domain is shown in SEQ ID NO:
16.
5. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR comprises a TCRα chain and a TCRβ chain, wherein the TCRα chain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 10; and / or the TCRβ chain variable domain is an amino acid sequence having at least 90% sequence identity with SEQ ID NO:
15.
6. The T cell receptor (TCR) according to claim 5, It is characterized in that The amino acid sequence of the α chain of the TCR is SEQ ID NO: 10; and / or The amino acid sequence of the β chain of the TCR is SEQ ID NO:
15.
7. The T cell receptor (TCR) according to claim 6, It is characterized in that The α chain amino acid sequence of the TCR is shown in SEQ ID NO: 10 and the β chain amino acid sequence is shown in SEQ ID NO:
15.
8. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR is soluble.
9. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR is a single-chain TCR.
10. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR is formed by connecting the α chain variable domain and the β chain variable domain via a peptide connecting sequence.
11. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR comprises (i) a TCR α chain variable domain and all or part of a TCR α chain constant region excluding a transmembrane domain; and (ii) a TCR β chain variable domain and all or part of a TCR β chain constant region excluding a transmembrane domain.
12. The T cell receptor (TCR) according to claim 1, It is characterized in that The TCR comprises an α chain variable domain and a β chain variable domain and all or part of the β chain constant domain excluding the transmembrane domain, but does not comprise an α chain constant domain, and the α chain variable domain of the TCR forms a heterodimer with the β chain.
13. The T cell receptor (TCR) according to claim 1, It is characterized in that A conjugate is bound to the C- or N-terminus of the α chain and / or β chain of the TCR; The conjugate bound to the T cell receptor is a detectable label.
14. An isolated nucleic acid molecule encoding the TCR of any one of claims 1-13.
15. A vector comprising the nucleic acid molecule according to claim 14.
16. The vector according to claim 15, It is characterized in that The vector is a viral vector.
17. The vector according to claim 16, It is characterized in that The vector is a lentiviral vector.
18. An isolated host cell, wherein the host cell contains the vector according to any one of claims 15 to 17 or the exogenous nucleic acid molecule according to claim 14 integrated into its genome.
19. A cell expressing the TCR of any one of claims 1-13 on its surface.
20. A cell according to claim 19, It is characterized in that The cell is transduced with the nucleic acid molecule of claim 14 or the vector of any one of claims 15-17.
21. The cell according to claim 20, It is characterized in that The cells are T cells, NK cells or stem cells.
22. The cell according to claim 21, It is characterized in that The T cells are NKT cells.
23. The cell according to claim 21, It is characterized in that The cells co-express the CD8 molecule.
24. The cell according to claim 23, It is characterized in that The CD8 molecule is a human CD8 molecule.
25. The cell according to claim 24, It is characterized in that The human CD8 molecule is a human CD8a molecule.
26. The cell according to claim 25, It is characterized in that The human CD8a molecule is a human CD8a molecule having the sequence shown in SEQ ID NO:
53.
27. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the TCR of any one of claims 1-13, the nucleic acid molecule of claim 14, the vector of any one of claims 15-17, or the cell of any one of claims 20-26.
28. Use of the T cell receptor according to any one of claims 1 to 13 and the cell according to any one of claims 20 to 26 for preparing a drug for treating tumors; The tumor is melanoma, non-small cell lung cancer, ovarian cancer, and breast cancer.
29. The use according to claim 28, It is characterized in that The tumor is non-small cell lung cancer.
